[Clinico-laboratory evaluation of the effectiveness of the new aminoglycoside antibiotic brulamycin (tobramycin) in treating surgical infections].
The clinico-laboratory estimation of brulamycin in the treatment of 50 patients with severe wound infections showed its high efficacy with respect to gram-negative microflora and in particular Ps. aeruginosa (94 per cent of the sensitive strains). Satisfactory into the affection foci and a long-term maintenance of its therapeutic levels in the host allowed one to recommend the antibiotic for the treatment of patients with complicated purulent affections and first of all systemic infections.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001419:Bacteria / Q000187:drug effects; D001770:Blood Bactericidal Activity / Q000187:drug effects; D004341:Drug Evaluation; D006801:Humans; D007700:Kinetics; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D013530:Surgical Wound Infection / Q000188:drug therapy* / Q000382:microbiology; D013997:Time Factors; D014031:Tobramycin / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*
D014031:Tobramycin
Kliniko-laboratornaia otsenka éffektivnosti novogo antibiotika-aminoglikozida brulamitsina (tobramitsin) v lechenii khirurgicheskoĭ infektsii.